These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35118240)

  • 41. Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice.
    Najima Y; Tomizawa-Murasawa M; Saito Y; Watanabe T; Ono R; Ochi T; Suzuki N; Fujiwara H; Ohara O; Shultz LD; Yasukawa M; Ishikawa F
    Blood; 2016 Feb; 127(6):722-34. PubMed ID: 26702062
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.
    Osada T; Woo CY; McKinney M; Yang XY; Lei G; Labreche HG; Hartman ZC; Niedzwiecki D; Chao N; Amalfitano A; Morse MA; Lyerly HK; Clay TM
    Clin Cancer Res; 2009 Apr; 15(8):2789-96. PubMed ID: 19351755
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.
    Uttenthal B; Martinez-Davila I; Ivey A; Craddock C; Chen F; Virchis A; Kottaridis P; Grimwade D; Khwaja A; Stauss H; Morris EC
    Br J Haematol; 2014 Feb; 164(3):366-75. PubMed ID: 24422723
    [TBL] [Abstract][Full Text] [Related]  

  • 44. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.
    Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M
    Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [WT1-targeting cancer vaccine].
    Sugiyama H
    Nihon Rinsho; 2012 Dec; 70(12):2105-13. PubMed ID: 23259381
    [TBL] [Abstract][Full Text] [Related]  

  • 46. WT1 peptide immunotherapy for cancer in children and young adults.
    Hashii Y; Sato E; Ohta H; Oka Y; Sugiyama H; Ozono K
    Pediatr Blood Cancer; 2010 Aug; 55(2):352-5. PubMed ID: 20582983
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules.
    Dao T; Korontsvit T; Zakhaleva V; Jarvis C; Mondello P; Oh C; Scheinberg DA
    Oncoimmunology; 2017; 6(2):e1252895. PubMed ID: 28344864
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies.
    Lippner EA; Lewis DB; Robinson WH; Katsumoto TR
    Curr Treat Options Oncol; 2019 Jun; 20(7):62. PubMed ID: 31227926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
    Jaigirdar A; Rosenberg SA; Parkhurst M
    J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
    Oka Y; Udaka K; Tsuboi A; Elisseeva OA; Ogawa H; Aozasa K; Kishimoto T; Sugiyama H
    J Immunol; 2000 Feb; 164(4):1873-80. PubMed ID: 10657636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.
    Clarke JM; Morse MA; Lyerly HK; Clay T; Osada T
    Expert Opin Biol Ther; 2010 Jun; 10(6):875-83. PubMed ID: 20380487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [WT1 Class I Peptide/WT1 Class II Peptide Pulsed Dendritic Cell Therapy Efficacy in 60 Patients with a Wide Range of Advanced Cancers].
    Kato Y
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1252-1255. PubMed ID: 27760951
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Wilms' tumor 1 gene in hematopoietic malignancies: clinical implications and future directions.
    Luo P; Jing W; Yi K; Wu S; Zhou F
    Leuk Lymphoma; 2020 Sep; 61(9):2059-2067. PubMed ID: 32401109
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis.
    Ariyaratana S; Loeb DM
    Expert Rev Mol Med; 2007 May; 9(14):1-17. PubMed ID: 17524167
    [TBL] [Abstract][Full Text] [Related]  

  • 56. WT1 peptide vaccination for the treatment of hematological malignancies: the present status and future direction.
    Oka Y; Tsuboi A; Shirakata T; Hosen N; Nishida S; Oji Y; Sugiyama H
    Rinsho Ketsueki; 2009 May; 50(5):352-7. PubMed ID: 19483394
    [No Abstract]   [Full Text] [Related]  

  • 57. Development of lymphopoiesis as a function of the thymic microenvironment. Use of CD8+ cytotoxic T lymphocytes for cellular immunotherapy of human cancer.
    Bodey B
    In Vivo; 1994; 8(5):915-43. PubMed ID: 7727741
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Wilms tumor gent 1 (WT1)-specific adoptive immunotherapy in hematologic diseases.
    Jiang Y; Lv X; Ge X; Qu H; Zhang Q; Lu K; Lu Y; Xue C; Zhang L; Wang X
    Int Immunopharmacol; 2021 May; 94():107504. PubMed ID: 33657524
    [TBL] [Abstract][Full Text] [Related]  

  • 59. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
    Dohi S; Ohno S; Ohno Y; Takakura M; Kyo S; Soma G; Sugiyama H; Inoue M
    Anticancer Res; 2011 Jul; 31(7):2441-5. PubMed ID: 21873157
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide.
    Ohminami H; Yasukawa M; Fujita S
    Blood; 2000 Jan; 95(1):286-93. PubMed ID: 10607714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.